Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab + Umbralisib Extension in CLL
NCT02656303Phase 2Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jan 2016
- Primary completion
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of ublituximab, umbralisib in chronic lymphocytic leukemia (CLL), sponsored by TG Therapeutics, Inc.. Started Jan 2016; status: terminated.
02
Drugs
ublituximabumbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02656303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656303.